News | Atrial Fibrillation | May 18, 2018

Botulinum Toxin Injection in CABG Patients Reduces AFib After Cardiac Surgery

Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

Figure 1: At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group


 

May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in patients undergoing coronary artery bypass grafting (CABG) has resulted in substantial atrial fibrillation (AF) suppression. The results were presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

There was sustained substantial reduction of atrial tachyarrhythmia incidence and AF burden in the early post-operative period, at one-year and three-year follow-up, data show.[1] This was accompanied by reduction in hospitalizations and major clinical adverse events. A large-scale multicenter randomized trial is needed to focus on hard clinical outcomes to more comprehensively test the value of botulinum toxin injections during cardiac surgery.

The study included 60 patients with history of paroxysmal AF and indications for CABG were randomized to either botulinum toxin (50U/1 ml at each fat pad; botox group; n=30) or placebo (0.9 percent normal saline, 1 ml at each fat pad; placebo group n=30) injections into four posterior epicardial fat pads. All patients received an ICM with regular follow-up. The primary endpoint of the extended follow up was incidence of any atrial tachyarrhythmia including AF and atrial tachycardia after 30 days of procedure until 36 months on no antiarrhythmic drugs. The secondary endpoints included clinical events and AF burden.

At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group (hazard ratio 0.36, 95 percent confidence interval 0.14-0.88, p= 0.026) See figure 1. The three-year AF burden was significantly lower in the botox group compared to the placebo group: 1.4 vs 6.9 percent (p < 0.001). In botox group, two (7 percent) patients were hospitalized during follow-up compared to 10 (33 percent) in placebo group (p=0.02); and there were no major clinical adverse events in botox group versus four patients (13 percent) in placebo group who developed stroke or died (p=0.1).

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

Reference:

1. Evgeny Pokushalov, Boris Kozlov, Alexander Romanov, et al. Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One Year Follow Up of a Randomized Pilot Study. Circulation: Arrhythmia and Electrophysiology. 2015;CIRCEP.115.003199. https://doi.org/10.1161/CIRCEP.115.003199
Originally published October 20, 2015.

Related Content

News | Atrial Fibrillation

July 29, 2022 — A cohort study of persons with incident atrial fibrillation (AF) has found that AF after noncardiac ...

Home July 29, 2022
Home
News | Atrial Fibrillation

July 20, 2022 — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial ...

Home July 20, 2022
Home
News | Atrial Fibrillation

July 6, 2022 — Atrial fibrillation (AF) is a prevalent cardiovascular condition with one of the highest rates of ...

Home July 06, 2022
Home
News | Atrial Fibrillation

June 30, 2022 — A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is ...

Home June 30, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science ...

Home May 02, 2022
Home
News | Atrial Fibrillation

April 12, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement ...

Home April 12, 2022
Home
News | Atrial Fibrillation

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
Subscribe Now